Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis.
5-Fluorouracil (5-FU) is a commonly used chemotherapy agent in clinical oncology practice. Two of its major side effects are mucositis and diarrhoea. The structure of mucins offers mucosal protection, and allows maintenance of intestinal flora by providing attachment sites and preventing bacterial overgrowth and/or penetration. The aim of this study was to investigate changes in mucin secretion and microflora following treatment with 5-FU. Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. Rats were killed at various time points after treatment. Control rats received no treatment. Jejunum, colon and faecal samples were collected. Standard microbiological culture techniques were used to identify bacteria, and real-time PCR was used to quantify bacteria in faecal samples. Goblet cells and cavitated goblet cells (having undergone mucus exocytosis) were also counted. Statistical analysis was carried out using Kruskal-Wallis test, a non-parametric method of testing equality of group medians. Following treatment with 5-FU, we showed decreases in Clostridium spp., Lactobacillus spp. and Streptococcus spp., and an increase in Escherichia spp. in the jejunum. In the colon, 5-FU caused decreases in Enterococcus spp., Lactobacillus spp. and Streptococcus spp. Real-time PCR of faecal samples showed decreasing trends in Lactobacillus spp. and Bacteroides spp., and an increasing trend in E. coli. Significant increases (P < 0.05) were seen in Clostridium spp. and Staphylococcus spp. at 24 h. Goblet cell numbers decreased significantly in the jejunum from 24-72 h, with a significant increase in the percentage of cavitated goblet cells. In conclusion, 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes could result in systemic effects and, in particular, may contribute to the development of chemotherapy-induced mucositis.
Stringer
Andrea M
AM
Dame Roma Mitchell Cancer Research Laboratory, Hanson Institute, Adelaide SA 5000, Australia. andrea.stringer@imvs.sa.gov.au
Gibson
Rachel J
RJ
Logan
Richard M
RM
Bowen
Joanne M
JM
Yeoh
Ann S J
AS
Hamilton
Juliette
J
Keefe
Dorothy M K
DM
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001419:Bacteria / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D015169:Colony Count, Microbial; D004573:Electrolytes / Q000097:blood; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology*; D005752:Gastric Mucins / Q000502:physiology*; D041981:Gastrointestinal Tract / Q000382:microbiology*; D020397:Goblet Cells / Q000187:drug effects / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D052016:Mucositis / Q000139:chemically induced* / Q000382:microbiology / Q000473:pathology; D051381:Rats; D011919:Rats, Inbred Strains
D000964:Antimetabolites, Antineoplastic; D004573:Electrolytes; D005752:Gastric Mucins; D005472:Fluorouracil